Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04683-3 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Romain Sechaud und 5 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG, Basel, CH-4002, Switzerland. romain.sechaud@novartis.com. Hauptthemen laut MEDLINE: Drug Interactions, Staurosporine, Cytochrome P-450 CYP2D6, ATP Binding Cassette Transporter, Subfamily G, Member 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Novartis.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Pharma AG, Basel, CH-4002, Switzerland. romain.sechaud@novartis.com.
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- Novartis Pharma AG, Basel, CH-4002, Switzerland.
- Parexel International GmbH-14050, Berlin, Germany.
Förderung
- Novartis
Zitieren
APA
Sechaud, R., Gu, H., Rahmanzadeh, G., Chiparus, O., Breitschaft, A., & Menssen, H. D. (2024). Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04683-3
Vancouver
Sechaud R, Gu H, Rahmanzadeh G, Chiparus O, Breitschaft A, Menssen HD. Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04683-3
BibTeX
@article{Sechaud2024,
author = {Sechaud, Romain and Gu, Helen and Rahmanzadeh, Gholamreza and Chiparus, Ovidiu and Breitschaft, Astrid and Menssen, Hans D},
title = {Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04683-3}
}
EUVIMED